查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596216

呼吸道疾病疫苗市场：依感染疾病、类型、年龄组别划分 - 全球预测 2025-2030 年

Respiratory Disease Vaccine Market by Infection (Influenza Virus, Pertussis, Streptococcus Pneumoniae), Type (Bacterial Vaccine, Combination Vaccine, Viral Vaccine), Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年呼吸道疾病疫苗市值为234.2亿美元，预计2024年将达到247.8亿美元，复合年增长率为5.87%，预计到2030年将达到349.3亿美元。

呼吸道疾病疫苗市场的范围和定义包括用于预防影响呼吸系统的疾病的疫苗的开发、生产和分销，例如流感、COVID-19和呼吸道融合细胞病毒（RSV）。世界上持续存在的呼吸道疾病负担凸显了对这些疫苗的需求，这些疾病造成了显着的发病率和死亡率，并影响了公共卫生系统和经济。呼吸道疫苗在季节性疫苗宣传活动和集体爆发应对措施中具有广泛的应用范围，从儿童到成人。最终用途范围主要针对医院和诊所等医疗机构，但也扩展到政府免疫计画和私人消费者。

主要市场统计
基准年[2023] 234.2亿美元
预测年份 [2024] 247.8亿美元
预测年份 [2030] 349.3亿美元
复合年增长率（%） 5.87%

市场成长的推动因素包括预防保健意识的增强、疫苗技术的进步以及政府对疫苗接种计划的支持。持续的COVID-19大流行进一步加速了该领域的投资和研究，为mRNA疫苗和鼻腔给药系统等创新提供了潜在机会。公司应专注于利用合作研究伙伴关係和资料分析来制定有效的市场渗透策略。然而，市场开拓面临开发成本高、监管障碍、人群远离疫苗等挑战。维持供应链完整性以及处理储存和分销物流也是主要限制因素。

为了利用这些机会，公司可以投资于开发提供更广泛保护的通用疫苗以及整合人工智慧进行预测模型以优化疫苗功效和分配等领域。低温运输物流的创新以及用于疫苗生产的植物和宿主载体系统的探索是未来成长的研究领域。该市场本质上是动态的、多学科的，涵盖生物技术、医学和资料分析，需要统一的方法才能取得成功。有效满足不断增长的需求、技术进步和监管合规性的公司将获得策略定位，以便在快速发展的呼吸道疾病疫苗市场中取得成功。

市场动态：快速发展的呼吸道疾病疫苗市场的关键市场洞察

供需的动态交互作用正在改变呼吸道疾病疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 呼吸道疾病盛行率增加
    • 临床试验和疫苗开发正在进行中
    • 政府支持呼吸健康的倡议
  • 市场限制因素
    • 医疗基础设施不足和意识有限
  • 市场机会
    • 主要企业研发费用增加
    • 透过转售合作伙伴关係增加疫苗的供应
  • 市场挑战
    • 消费者对呼吸道疾病疫苗接种的信任与信心

波特五力：驾驭呼吸道疾病疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解呼吸道疾病疫苗市场的外部影响

外部宏观环境因素对呼吸道疾病疫苗市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解呼吸道疾病疫苗市场的竞争格局

对呼吸系统疾病疫苗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵呼吸道疾病疫苗市场供应商的绩效评估

FPNV 定位矩阵是评估呼吸道疾病疫苗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划呼吸道疾病疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对呼吸道疾病疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 呼吸道疾病盛行率增加
      • 临床试验和疫苗开发正在进行中
      • 政府支持呼吸健康的倡议
    • 抑制因素
      • 配送基础设施薄弱且意识缺乏
    • 机会
      • 主要企业研发费用增加
      • 透过转售合作增加疫苗的供应
    • 任务
      • 消费者对呼吸道疾病疫苗的信任与信心
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 呼吸道疾病疫苗市场受感染状况

  • 流感病毒
  • 百日咳
  • 肺炎球菌
  • 结核

第七章呼吸系统疾病疫苗市场：依类型

  • 细菌疫苗
  • 联合疫苗
  • 病毒疫苗

第八章呼吸道疾病疫苗市场：依年龄组别

  • 青少年疫苗接种
  • 成人疫苗接种
  • 婴儿疫苗接种

第九章美洲呼吸道疾病疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太呼吸道疾病疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲呼吸道疾病疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astrazeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • CanSino Biologics Inc.
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus USA Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Vaxine Pty Ltd.
Product Code: MRR-035AB9C0DAB0

The Respiratory Disease Vaccine Market was valued at USD 23.42 billion in 2023, expected to reach USD 24.78 billion in 2024, and is projected to grow at a CAGR of 5.87%, to USD 34.93 billion by 2030.

The scope and definition of the respiratory disease vaccine market encompass the development, production, and distribution of vaccines aimed at preventing diseases affecting the respiratory system, such as influenza, COVID-19, and respiratory syncytial virus (RSV). The necessity of these vaccines is underscored by the persistent global burden of respiratory illnesses, which cause significant morbidity and mortality, impacting public health systems and economies. The application of respiratory vaccines is robust, involving both pediatric and adult populations, and spans both seasonal vaccination campaigns and outbreak response initiatives. End-use scope primarily covers healthcare institutions, including hospitals and clinics, and extends to government vaccination programs and individual consumers.

KEY MARKET STATISTICS
Base Year [2023] USD 23.42 billion
Estimated Year [2024] USD 24.78 billion
Forecast Year [2030] USD 34.93 billion
CAGR (%) 5.87%

Market growth is driven by factors such as increasing awareness about preventive healthcare, advances in vaccine technologies, and governmental support for vaccination programs. The ongoing COVID-19 pandemic has further accelerated investments and research in this sector, providing potential opportunities for innovations like mRNA vaccines and intranasal delivery systems. Companies should focus on collaborative research partnerships and leveraging data analytics for effective market penetration strategies. However, market growth faces challenges like high development costs, regulatory hurdles, and vaccine hesitancy among populations. Maintaining supply chain integrity and addressing storage and distribution logistics also pose significant limitations.

To capitalize on these opportunities, businesses can invest in areas like the development of universal vaccines that offer broader protection and the integration of artificial intelligence for predictive modeling in vaccine efficacy and distribution optimization. Innovation in cold chain logistics and exploring plant-based and host-vector systems for vaccine production are promising research areas for future growth. The market is dynamic, with a multidisciplinary nature that spans biotechnology, medical science, and data analytics, requiring a harmonized approach for success. Companies that effectively address the rising demand, technological advancements, and regulatory compliance will be strategically positioned to thrive in the rapidly evolving respiratory disease vaccine market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Disease Vaccine Market

The Respiratory Disease Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of respiratory disorders
    • Clinical trials and vaccines developments in pipeline
    • Government initiatives supporting respiratory health
  • Market Restraints
    • Lack of inadequate delivery infrastructure & limited awareness
  • Market Opportunities
    • Increasing R&D expenditure by leading companies
    • Increase vaccine availability through reselling collaborations
  • Market Challenges
    • Consumer trust & confidence in respiratory disease vaccination

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Disease Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Disease Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Disease Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Disease Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Disease Vaccine Market

A detailed market share analysis in the Respiratory Disease Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Disease Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Disease Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Disease Vaccine Market

A strategic analysis of the Respiratory Disease Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Disease Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astrazeneca PLC, Bavarian Nordic A/S, Bharat Biotech International Ltd., CanSino Biologics Inc., Emergent BioSolutions, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Sanofi S.A., Seqirus USA Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Vaxine Pty Ltd..

Market Segmentation & Coverage

This research report categorizes the Respiratory Disease Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Infection, market is studied across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis.
  • Based on Type, market is studied across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
  • Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of respiratory disorders
      • 5.1.1.2. Clinical trials and vaccines developments in pipeline
      • 5.1.1.3. Government initiatives supporting respiratory health
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of inadequate delivery infrastructure & limited awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D expenditure by leading companies
      • 5.1.3.2. Increase vaccine availability through reselling collaborations
    • 5.1.4. Challenges
      • 5.1.4.1. Consumer trust & confidence in respiratory disease vaccination
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Respiratory Disease Vaccine Market, by Infection

  • 6.1. Introduction
  • 6.2. Influenza Virus
  • 6.3. Pertussis
  • 6.4. Streptococcus Pneumoniae
  • 6.5. Tuberculosis

7. Respiratory Disease Vaccine Market, by Type

  • 7.1. Introduction
  • 7.2. Bacterial Vaccine
  • 7.3. Combination Vaccine
  • 7.4. Viral Vaccine

8. Respiratory Disease Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adolescent Vaccination
  • 8.3. Adult Vaccination
  • 8.4. Infant Vaccination

9. Americas Respiratory Disease Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Respiratory Disease Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Disease Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astrazeneca PLC
  • 2. Bavarian Nordic A/S
  • 3. Bharat Biotech International Ltd.
  • 4. CanSino Biologics Inc.
  • 5. Emergent BioSolutions, Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Moderna, Inc.
  • 10. Pfizer Inc.
  • 11. Sanofi S.A.
  • 12. Seqirus USA Inc.
  • 13. Serum Institute of India Pvt. Ltd.
  • 14. Sinovac Biotech Ltd.
  • 15. Vaxine Pty Ltd.

LIST OF FIGURES

  • FIGURE 1. RESPIRATORY DISEASE VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. RESPIRATORY DISEASE VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RESPIRATORY DISEASE VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RESPIRATORY DISEASE VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023